The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ERIC 2024 | Addressing gaps in the treatment and diagnosis of CLL in low- and middle-income countries
Miguel Pavlovsky, MD, University of Buenos Aires, Buenos Aires, Argentina, highlights the challenges faced by low- and middle-income countries in accessing diagnostics and treatments for chronic lymphocytic leukemia (CLL). He underscores the importance of clinical trials and collaborative international efforts in improving access. This interview took place at the 2024 European Research Initiative on CLL (ERIC) Meeting in Barcelona, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Travel support: AstraZeneca, Abbvie, Rush, Merck Sharp & Dohme, Johnson & Johnson
